Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Sun Pharma Reported Bid For Bausch & Lomb And Meda Raises Hopes For Bigger Buyouts

This article was originally published in PharmAsia News

Executive Summary

Sun Pharma has been increasingly linked to a potential global deal in the branded and specialty segments. With former Teva CEO Israel Makov as Sun’s chairman, and robust earnings continuing to pour in, a deal may be just around the corner.

Advertisement

Related Content

Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084474

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel